(Total Views: 708)
Posted On: 10/17/2018 9:50:48 AM
Post# of 72446
Not in SEC filings, but in press release on 9/20/2018.
Link
http://www.ipharminc.com/press-release/2018/9...and-events
Quote:
"In coming weeks, the Company plans to submit a request for an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) to discuss appropriate next steps in the development of Brilacidin for the treatment of Oral Mucositis (OM), which has already been granted Fast Track designation. A Breakthrough Therapy Designation application is currently under review with the FDA."
Link
http://www.ipharminc.com/press-release/2018/9...and-events
(1)
(0)
